Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy
Cancers · 15.07.2023 · 15 (14) · 3638
DOI: 10.3390/cancers15143638 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 15.07.2023. Verfasst von Manuel Scimeca und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133 Rome, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Min Salute-PNRR, Italian Association for Cancer Research, PNCHLS-DA project INNOVA Diagnostica Avanzata.
Abstract (Originalsprache)
Cholangiocarcinoma is a highly aggressive cancer arising from the bile ducts. The limited effectiveness of conventional therapies has prompted the search for new approaches to target this disease. Recent evidence suggests that distinct programmed cell death mechanisms, namely, apoptosis, ferroptosis, pyroptosis and necroptosis, play a critical role in the development and progression of cholangiocarcinoma. This review aims to summarize the current knowledge on the role of programmed cell death in cholangiocarcinoma and its potential implications for the development of novel therapies. Several studies have shown that the dysregulation of apoptotic signaling pathways contributes to cholangiocarcinoma tumorigenesis and resistance to treatment. Similarly, ferroptosis, pyroptosis and necroptosis, which are pro-inflammatory forms of cell death, have been implicated in promoting immune cell recruitment and activation, thus enhancing the antitumor immune response. Moreover, recent studies have suggested that targeting cell death pathways could sensitize cholangiocarcinoma cells to chemotherapy and immunotherapy. In conclusion, programmed cell death represents a relevant molecular mechanism of pathogenesis in cholangiocarcinoma, and further research is needed to fully elucidate the underlying details and possibly identify therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133 Rome, Italy.
- Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
- Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
- Institute Pasteur Italy-Cenci Bolognetti Foundation, Via Regina Elena 291, 00161 Rome, Italy.
- IRCCS Neuromed S.p.A., Via Atinense 18, 86077 Pozzilli, Italy.
ORCID-Profile: Manuel Scimeca, Valentina Rovella, Valeria Palumbo, Massimiliano Agostini, Alessandro Mauriello
Förderung
- Min Salute-PNRR
- Italian Association for Cancer Research
- PNCHLS-DA project INNOVA Diagnostica Avanzata
- Associazione Italiana per la Ricerca contro il Cancro (AIRC)
- EC
Zitieren
APA
Scimeca, M., Rovella, V., Palumbo, V., Scioli, M. P., Bonfiglio, R., Tor Centre, Melino, G., Piacentini, M., Frati, L., Agostini, M., Candi, E., & Mauriello, A. (2023). Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy. Cancers, 15(14), 3638. https://doi.org/10.3390/cancers15143638
Vancouver
Scimeca M, Rovella V, Palumbo V, Scioli MP, Bonfiglio R, Tor Centre, et al. Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy. Cancers. 2023;15(14):3638. doi:10.3390/cancers15143638
BibTeX
@article{Scimeca2023,
author = {Scimeca, Manuel and Rovella, Valentina and Palumbo, Valeria and Scioli, Maria Paola and Bonfiglio, Rita and Tor Centre and Melino, Gerry and Piacentini, Mauro and Frati, Luigi and Agostini, Massimiliano and Candi, Eleonora and Mauriello, Alessandro},
title = {Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy},
journal = {Cancers},
year = {2023},
volume = {15},
number = {14},
pages = {3638},
doi = {10.3390/cancers15143638}
}
EUVIMED